Clinical Trial Update: Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of SU11248 (sunitinib malate) in patients with metastatic colorectal cancer who had failed prior treatments.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED